Advertisement

Current Urology Reports

, 20:1 | Cite as

A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma

  • Caroline E. Nunes-Xavier
  • Javier C. Angulo
  • Rafael Pulido
  • José I. LópezEmail author
Kidney Diseases (G Ciancio, Section Editor)
  • 163 Downloads
Part of the following topical collections:
  1. Topical Collection on Kidney Diseases

Abstract

Purpose of Review

Targeting PD-1/PD-L1 immune checkpoints is a new therapeutic tool in patients with locally advanced and metastatic clear cell renal cell carcinoma (CCRCC). The purpose of this review is to offer clinicians an updated translational insight into the current status of a therapeutic alternative that may impact significantly patient’s life.

Recent Findings

Immune checkpoint inhibition has recently demonstrated promising results in selected CCRCC patients with respect to tumor progression and survival. The decision to treat these patients with immune checkpoint inhibitors (ICI) relies on the immunohistochemical detection of PD-1/PD-L1 positivity in inflammatory cells in the tumor, which makes the role of the pathologist crucial, but clinical concern upon the reliability to use immunohistochemistry (IHC) to predict therapeutic response is increasing.

Summary

We review the state of the art of the immune checkpoint inhibition in CCRCC, from the basic science and its fundamentals to the daily application in clinical routine.

Keywords

Clear cell renal cell carcinoma Immune checkpoint inhibition PD-1 PD-L1 Immunohistochemistry Sampling protocols Targeted therapy 

Notes

Funding

This work has been partially funded by grants SAF2016-79847-R from Ministerio de Economía y Competitividad, Spain (to RP and JIL) and 239813 from The Norwegian Research Council, Norway (to CEN-X).

Compliance with Ethical Standards

Conflict of Interest

Caroline E. Nunes-Xavier, Javier C. Angulo, Rafael Pulido, and José I. López each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.PubMedGoogle Scholar
  2. 2.
    López JI. Renal tumors with clear cells. A review. Pathol Res Pract. 2013;209:137–46.PubMedGoogle Scholar
  3. 3.
    Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Zaldumbide L, Erramuzpe A, Guarch R, Cortés JM, López JI. Large (>3.8 cm) clear cell renal cell carcinomas are morphologically and immunohistochemically heterogeneous. Virchows Arch. 2015;466:61–6.PubMedGoogle Scholar
  5. 5.
    Guarch R, Lawrie CH, Larrinaga G, Angulo JC, Pulido R, López JI. High levels of intratumor heterogeneity characterize the expression of epithelial-mesenchymal transition markers in high grade clear cell renal cell carcinoma. Ann Diagn Pathol. 2018;34:27–30.PubMedGoogle Scholar
  6. 6.
    •• Turajlic S, Xu H, Litchfield K, et al. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx Renal. Cell. 2018;173:595–610. This paper describes for the first time 7 different evolutionary subtypes with impact on survival and exemplifies the complexity of intratumor heretogeneity of clear cell renal cell carcinoma. Google Scholar
  7. 7.
    •• Turajlic S, Xu H, Litchfield K, et al. Tracking renal cancer evolution reveals constrained routes to metastases: TRACERx Renal. Cell. 2018;173:581–94. Two different temporal patterns of metastases, early and late, are described after a genomic study in clear cell renal cell carcinoma. Google Scholar
  8. 8.
    Atkins MB, Tannir NM. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev. 2018;70:127–37.PubMedGoogle Scholar
  9. 9.
    Messai Y, Gad S, Noman MZ, le Teuff G, Couve S, Janji B, et al. Renal cell carcinoma programmed death-ligand 1, a new direct target of hypoxia-inducible factor-2 alpha, is regulated by von Hippel-Lindau gene mutation status. Eur Urol. 2016;70:623–32.PubMedGoogle Scholar
  10. 10.
    Ruf M, Moch H, Schaml P. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. Int J Cancer. 2016;139:396–403.PubMedGoogle Scholar
  11. 11.
    Kammerer-Jacquet SF, Crouzet L, Brunot A, et al. Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma. A finding with therapeutic potential. Int J Cancer. 2016;140:142–8.PubMedGoogle Scholar
  12. 12.
    Khagi Y, Kurzrock R, Patel SP. Next generation predictive biomarkers for immune checkpoint inhibition. Cancer Metastasis Rev. 2017;36:179–90.PubMedPubMedCentralGoogle Scholar
  13. 13.
    • Turajlic S, Swanton C, Boshoff C. Kidney cancer: the next decade. J Exp Med. 2018;215: 2477–79. This short review offers an insight into the upcoming therapeutic strategies in renal cell carcinoma. Google Scholar
  14. 14.
    López JI, Pulido R, Cortés JM, Angulo JC, Lawrie CH. Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy. Pathol Res Pract. 2018;214:1110–4.PubMedGoogle Scholar
  15. 15.
    López JI, Pulido R, Lawrie CH, Angulo JC. Loss of PD-L1 (SP-142) expression characterizes renal vein tumor thrombus microenvironment in clear cell renal cell carcinoma. Ann Diagn Pathol. 2018;34:89–93.PubMedGoogle Scholar
  16. 16.
    Munari E, Zamboni G, Lunardi G, Marchionni L, Marconi M, Sommaggio M, et al. PD-L1 expression heterogeneity in non-small cell lung cancer: defining criteria for harmonization between biopsy specimens and whole sections. J Thorac Oncol. 2018;13:1113–20.PubMedGoogle Scholar
  17. 17.
    Ascierto ML, McMiller TL, Berger AE, et al. The intratumoral balance between metabolic and immunologic gene expression is associated with anti-PD-1 response in patients with renal cell carcinoma. Cancer Immunol Res. 2016;4:726–33.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Finger LR, Pu J, Wasserman R, Vibhakar R, Louie E, Hardy RR, et al. The human PD-1 gene : complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors. Gene. 1997;197:177–87.PubMedGoogle Scholar
  19. 19.
    Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–34.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunol. 2001;2:261–8.Google Scholar
  21. 21.
    Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Ann Rev Immunol. 2005;23:515–48.Google Scholar
  22. 22.
    Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B-cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A. 2001;98:13866–71.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Sheppard KA, Fitz LJ, Lee JM, Benander C, George JA, Wooters J, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 2004;574:37–41.PubMedGoogle Scholar
  24. 24.
    Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Ann Rev Immunol. 2008;26:677–704.Google Scholar
  25. 25.
    Dong Y, Sun Q, Zhang X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget. 2017;8:2171–86.PubMedGoogle Scholar
  26. 26.
    Nielsen C, Ohm-Laursen L, Barington T, Husby S, Lillevang ST. Alternative splice variants of the human PD-1 gene. Cell Immunol. 2005;235:109–16.PubMedGoogle Scholar
  27. 27.
    Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, coestimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365–9.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Escors D, Gato-Canas M, Zuazo M, et al. The intracelular signalosome of PD-L1 in cancer cells. Signal Transduct Target Ther. 2018;3:26.PubMedPubMedCentralGoogle Scholar
  29. 29.
    He XH, Liu Y, Xu LH, Zeng YY. Cloning and identification of two novel splice variants of human PD-L2. Acta Biochim Biophys Sinica. 2004;36:284–9.Google Scholar
  30. 30.
    He XH, Xu LH, Liu Y. Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain. Acta Pharmacol Sinica. 2005;26:462–8.Google Scholar
  31. 31.
    Ding H, Wu X, Gao W. PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis. Clin Immunol. 2005;115:184–91.PubMedGoogle Scholar
  32. 32.
    Chen Y, Zhang J, Li J, Zou L, Zhao T, Tang Y, et al. Expression of B7-H1 in inflammatory renal tubular epithelial cells. Nephron Exp Nephrol. 2006;102:e81–92.PubMedGoogle Scholar
  33. 33.
    Zhang J, Chen Y, Li J, et al. Renal tubular epithelial expression of the coinhibitory molecule B7-DC (programmed death-1 ligand). J Nephrol. 2006;19:429–38.PubMedGoogle Scholar
  34. 34.
    Frigola X, Inman BA, Lohse CM, Krco CJ, Cheville JC, Thompson RH, et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res. 2011;17:1915–23.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Yao H, Wang H, Li C, Fang JY, Xu J. Cancer cell-intrinsic PD-1 and implications in combinatorial immunotherapy. Front Immunol. 2018;9:1774.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Folkl A, Bienzle D. Structure and function of programmed death (PD) molecules. Vet Immunol Immunopathol. 2010;134:33–8.PubMedGoogle Scholar
  37. 37.
    Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13:1757–61.PubMedGoogle Scholar
  38. 38.
    MacFarlane AW 4th, Jillab M, Plimack ER, et al. PD-1 expression on peripheral blood cells increaseswith stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res. 2014;2:320–31.PubMedGoogle Scholar
  39. 39.
    Mazanet MM, Hughes CC. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol. 2002;169:3581–8.PubMedGoogle Scholar
  40. 40.
    Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role of pro-survival signaling in cancer. Ann Oncol. 2016;27:409–16.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Gibbons-Johnson RM, Dong H. Functional expression of programmed death-ligand 1 (B7-H1) by immune cells and tumor cells. Front Immunol. 2017;8:961.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211:781–90.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Tatli Dogan H, Kiran M, Bilgin B, Kiliçarslan A, Sendur MAN, Yalçin B, et al. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression. Diagn Pathol. 2018;13:60.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004;173:945–54.PubMedGoogle Scholar
  45. 45.
    Kulpa DA, Lawani M, Cooper A, Peretz Y, Ahlers J, Sekaly RP. PD-1 coinhibitory signals: the link between pathogenesis and protection. Semin Immunol. 2013;25:219–27.PubMedGoogle Scholar
  46. 46.
    Patsoukis N, Brown J, Petkova V, Liu F, Li L, Boussiotis VA. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Sign. 2012;5:ra46.Google Scholar
  47. 47.
    Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA. PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2. Mol Cell Biol. 2013;33:3091–8.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016;6:202–16.PubMedGoogle Scholar
  49. 49.
    George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, et al. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity. 2017;46:197–204.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Brenner W, Farber G, Herget T, Lehr HA, Hengstler JG, Thuroff JW. Loss of tumor suppressor protein PTEN during renal carcinogénesis. Int J Cancer. 2002;99:53–7.PubMedGoogle Scholar
  51. 51.
    Shin Lee J, Seok Kim H, Bok Kim Y, Cheol Lee M, Soo PC. Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. J Surg Oncol. 2003;84:166–72.PubMedGoogle Scholar
  52. 52.
    Hager M, Haufe H, Kemmerling R, Mikuz G, Kolbitsch C, Moser PL. PTEN expression in renal cell carcinoma and oncocytoma and prognosis. Pathology. 2007;39:482–5.PubMedGoogle Scholar
  53. 53.
    Dong P, Xiong Y, Yue J, Hanley SJB, Watari H. Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion. Front Oncol. 2018;8:385.Google Scholar
  54. 54.
    Gupta HB, Clark CA, Yuan B, Sareddy G, Pandeswara S, Padron AS, et al. Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. Sign Transduct Target Ther. 2016;1:16030.Google Scholar
  55. 55.
    Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, et al. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res. 2016;76:6964–74.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Qiu XY, Hu DX, Chen WQ, et al. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation. Biochim Biophys Acta Mol basis Dis. 1864;2018:1754–69.Google Scholar
  57. 57.
    Wang Y, Wang H, Zhao Q, Xia Y, Hu X, Guo J. PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma. Med Oncol. 2015;32:212.PubMedGoogle Scholar
  58. 58.
    Verbiest A, Couchy G, Job S, Zucman-Rossi J, Caruana L, Lerut E, et al. Molecular subtypes of clear cell renal cell carcinoma are associated with outcome during pazopanib therapy in the metastatic setting. Clin Genitourin Cancer. 2018;16:e605–12.PubMedGoogle Scholar
  59. 59.
    Iacovelli R, Nole F, Verri E, et al. Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis. Targ Oncol. 2016;11:143–8.Google Scholar
  60. 60.
    Wang Z, Peng S, Xie H, Guo L, Cai Q, Shang Z, et al. Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals. Clin Exp Med. 2018;18:165–75.PubMedGoogle Scholar
  61. 61.
    Abbas M, Steffens S, Bellut M, Eggers H, Großhennig A, Becker JU, et al. Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). Med Oncol. 2016;33:80.PubMedGoogle Scholar
  62. 62.
    Ueda K, Suekane S, Kurose H, Chikui K, Nakiri M, Nishihara K, et al. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma. Urol Oncol. 2018;36:499.e9–499.e16.  https://doi.org/10.1016/j.uroloncol.2018.07.003.CrossRefGoogle Scholar
  63. 63.
    Thompson RH, Kuntz SM, Leibovitz BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66:3381–5.PubMedGoogle Scholar
  64. 64.
    • Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Eng J Med. 2017;376:354–66. Exhaustive review of the spectrum of systemic therapies available for patients with advanced renal cancer. Google Scholar
  65. 65.
    Flynn M, Pickering L, Larkin J, Turajlic S. Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. Ther Adv Med Oncol. 2018;10:1–16.Google Scholar
  66. 66.
    Liang J, Liu Z, Zou Z, Tang Y, Zhou C, Yang J, et al. The correlation between the immune and epithelial-mesenchymal transition signatures suggests potential therapeutic targets and prognosis prediction approaches in kidney cancer. Sci Rep. 2018;8:6570.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Beckermann KE, Douglas B, Johnson DB, Sosman JA. PD-1/PD-L1 blockade in renal cell cancer. Expert Rev Clin Immunol. 2017;13:77–84.PubMedGoogle Scholar
  68. 68.
    Nassar A, Radhakrishan A, Cabrero IA, Cotsonis GA, Cohen C. Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma. A tissue microarray-based study. Appl Immunohistochem Mol Morphol. 2010;18:433–41.PubMedGoogle Scholar
  69. 69.
    Jilaveanu LB, Shuch B, Zito CR, Parisi F, Barr M, Kluger Y, et al. PD-L1 expression in clear cell renal cell carcinoma: an analysis of nephrectomy and sites of metastases. J Cancer. 2014;5:166–72.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Ellsworth RE, Blackburn HL, Shriver CD, Soon-Shiong P, Ellsworth DL. Molecular heterogeneity in breast cancer: state of the science and implications for patient care. Semin Cell Dev Biol. 2017;64:65–72.PubMedGoogle Scholar
  71. 71.
    • López JI, Cortés JM. A divide and conquer strategy in tumor sampling enhances detection of intratumor heterogeneity in pathology routine: a modeling approach in clear cell renal cell carcinoma. F1000Res. 2016;5:385. This paper describes an in silico approach to a new sampling method that improves intratumor heterogeneity detection in large tumors. Google Scholar
  72. 72.
    López JI, Cortés JM. Multi-site tumor sampling (MSTS): a new tumor selection method to enhance intratumor heterogeneity detection. Hum Pathol. 2017;64:1–6.PubMedGoogle Scholar
  73. 73.
    Ming D, Yang W. A divide and conquer strategy to improve diffusion sampling in generalized ensemble simulators. J Chem Phys. 2008;128:094106.Google Scholar
  74. 74.
    Kristensen VN. Divide and conquer: the genetic basis of molecular subclassification of breast cancer. EMBO Mol Med. 2011;3:183–5.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Horita H, Law A, Hong S, Middleton K. Identifying regulatory posttranscriptional modifications of PD-L1: a focus on monoubiquitination. Neoplasia. 2017;19:346–53.PubMedPubMedCentralGoogle Scholar
  76. 76.
    Shin SJ, Jeon YK, Kim PJ, Cho YM, Koh J, Chung DH, et al. Clinicopathologic analysis of PD-L1 and PD-L2 expression in renal cell carcinoma: association with oncogenic proteins status. Ann Surg Oncol. 2016;23:694–702.PubMedGoogle Scholar
  77. 77.
    Hendry S, Bryne DJ, Wright GM, et al. Comparison of four PD-L1 immunohistochemical assays in lung cancer. J Thorac Oncol. 2017;13:367–76.PubMedGoogle Scholar
  78. 78.
    Adam J, Le Stang N, Rouquette I, et al. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. Ann Oncol. 2018;29:953–8.PubMedGoogle Scholar
  79. 79.
    Tsao MS, Kerr KM, Kockx M, Beasley MB, Borczuk AC, Botling J, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol. 2018;13:1302–11.PubMedGoogle Scholar
  80. 80.
    Munari E, Rossi G, Zamboni G, Lunardi G, Marconi M, Sommaggio M, et al. PD-L1 assays 22C3 and SP263 are not interchangeable in non-small cell lung cancer when considering clinically relevant cutoffs. An interclon evaluation by differently trained pathologists. Am J Surg Pathol. 2018;42:1384–9.PubMedGoogle Scholar
  81. 81.
    Brunnström H, Johansonn A, Westbom-Fremer S, et al. PD-L1 immunohistochemistry in clinical diagnosis of lung cancer: inter-pathologist variability is higher than assay variability. Mod Pathol. 2017;30:1411–21.PubMedGoogle Scholar
  82. 82.
    Wang C, Hahn E, Slodkowska E, Eskander A, Enepekides D, Higgins K, et al. Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types. Hum Pathol. 2018;82:131–9.  https://doi.org/10.1016/j.humpath.2018.07.024.CrossRefPubMedGoogle Scholar
  83. 83.
    Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm. Multicenter, phase 2 trial. Lancet. 2016;387:1909–20.PubMedPubMedCentralGoogle Scholar
  84. 84.
    •• Ross K, Jones RJ. Immune checkpoint inhibitors in renal cell carcinoma. Clin Sci. 2017;131:2627–42. Excellent review of the current status of immune checkpoint blockade in renal cell carcinoma. Google Scholar
  85. 85.
    • Özdemir BC, Siefker-Radtke AO, Campbell MT, Subudhi SK. Current and future applications of novel immunotherapies in urological oncology: a critical review of the literature. Eur Urol Focus. 2017,  https://doi.org/10.1016/j.euf.2017.10.001. A review on the clinical data for immune checkpoint inhibition alone or in combination with other therapies for urologic malignancies.
  86. 86.
    Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33:1430–7.PubMedGoogle Scholar
  87. 87.
    •• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–1813. This phase 3 randomized study demonstrated that patients with advanced renal cell carcinoma experienced longer survival with nivolumab treatment than with everolimus treatment after prior antiangiogenic treatment. Google Scholar
  88. 88.
    George S, Motzer RJ, Hammers HJ, Redman BG, Kuzel TM, Tykodi SS, et al. Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial. JAMA Oncol. 2016;2:1179–86.PubMedPubMedCentralGoogle Scholar
  89. 89.
    • Bedke J, Stühler V, Stenzl A, Brehmer B. Immunotherapy for kidney cancer: status quo and the future. Curr Opin Urol. 2018;28:8–14. Essential review on the immunotherapy for renal cell cancer, including both checkpoint inhibitors and vaccination strategies. Google Scholar
  90. 90.
    Bedke J, Gauler T, Grünwald V, Hegele A, Herrmann E, Hinz S, et al. Systemic therapy in metastatic renal cell carcinoma. World J Urol. 2017;35:179–88.PubMedGoogle Scholar
  91. 91.
    Atkins MB, Philips GK. Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC). Expert Opin Emerg Drugs. 2016;21:243–54.PubMedGoogle Scholar
  92. 92.
    Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277–90.PubMedPubMedCentralGoogle Scholar
  93. 93.
    Bedke J, Stenzl A. IMA901: a peptide vaccine in renal cell carcinoma. Expert Opin Investig Drugs. 2013;22:1329–36.PubMedGoogle Scholar
  94. 94.
    Rini BI, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S, et al. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicenter open-label, randomized, controlled phase 3 trial. Lancet Oncol. 2016;17:1599–611.PubMedGoogle Scholar
  95. 95.
    Maleki Vareki S, Garrigós C, Duran I. Biomarkers of response to PD-1/PD-L1 inhibition. Crit Rev Oncol Hematol. 2017;116:116–24.PubMedGoogle Scholar
  96. 96.
    Nishijima TF, Shachar SS, Nyrop KA, Muss HB. Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist. 2017;22:470–9.PubMedPubMedCentralGoogle Scholar
  97. 97.
    Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714–68.Google Scholar
  98. 98.
    •• Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ. 2018;362:k3529. Meta-analysis that proves PD-L1 expression status is insufficient to determine patients that should be offered PD-1 or PD-L1 blockade therapy. Google Scholar
  99. 99.
    • Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17:e542–51. Extensive review dealing with the pitfalls and possibilities to define accurate predictive biomarkers for checkpoint inhibition. Google Scholar
  100. 100.
    Baxi S, Yang A, Gennarelli RL, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018;360:k793.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Caroline E. Nunes-Xavier
    • 1
    • 2
  • Javier C. Angulo
    • 3
    • 4
  • Rafael Pulido
    • 1
    • 5
  • José I. López
    • 1
    • 6
    • 7
    Email author
  1. 1.Biomarkers in Cancer UnitBiocruces-Bizkaia Health Research InstituteBarakaldoSpain
  2. 2.Department of Tumor Biology, Institute for Cancer ResearchOslo University Hospital RadiumhospitaletOsloNorway
  3. 3.Department of UrologyUniversity Hospital of GetafeGetafeSpain
  4. 4.Clinical DepartmentEuropean University of Madrid, Laureate UniversitiesMadridSpain
  5. 5.IKERBASQUE, The Basque Foundation for ScienceBilbaoSpain
  6. 6.Department of PathologyCruces University HospitalBarakaldoSpain
  7. 7.Department of Medical-Surgical SpecialtiesUniversity of the Basque Country (UPV/EHU)LeioaSpain

Personalised recommendations